# Resource for Molecular Imaging Agents in Precision Medicine

> **NIH NIH P41** · UT SOUTHWESTERN MEDICAL CENTER · 2024 · $1,436,774

## Abstract

The Resource for Molecular Imaging Agents in Precision Medicine is a transdisciplinary consortium of
facilities and expertise centered at Johns Hopkins University. Participants are the Russell H. Morgan Department
of Radiology and Radiological Science, the F. M. Kirby Research Center at the Kennedy Krieger Institute, the
Sidney Kimmel Comprehensive Cancer Center, and the Department of Biomedical Engineering, with key
industrial collaborators in biomedical imaging and pharmaceuticals to ensure widespread dissemination. Our
work will synthesize, develop, and deploy precision imaging tools and theranostic agents for early detection,
interception, and cure. The long-term objective of the NCBIB is to promote the translation and dissemination of
new molecular imaging and theranostic agents and their attendant best practices along the spectrum of cancer,
inflammation and immunity. Our proposed work capitalizes on advances made in the past five years in artificial
intelligence (AI), new and more sensitive translational imaging devices, nanotechnology, gene manipulation, and
new techniques to produce specific molecular affinity agents and will create a scientific ecosystem that can
transform the healthcare landscape. Collaborative academic centers such as ours, while steeped in the culture
of fundamental discovery, are beginning to pivot toward the development of new work products – working
backwards from unmet needs – in the context of increasing academic-industrial partnerships and
entrepreneurship. Working closely with our partners, we will leverage these advances in scientific and academic
cultural thinking, and provide new materials to our collaborating and service partners, some of whom have
worldwide reach, to address pressing and unsolved medical challenges. During the first funding period we
consolidated our ability to work together seamlessly as a NCBIB; in this renewal, we have added collaboration
with a new local NCBIB that complements our work by providing biological reagents relevant to
immunoengineering, offering AI capability, founding one company dedicated to advancing use of AI in molecular
imaging and another company for commercialization of imaging and theranostic agents, received FDA approval
for an imaging agent (analogs of which are already in use in the NCBIB), and providing precursors, other
reagents and IND cross-references to multiple institutions. Our goals for the renewal period are, across four
TR&Ds, to develop: new reagents to detect and promote an immune reactive tumor microenvironment (TR&D1);
an integrated nanoplatform to manage a variety of cancers (TR&D2); translational imaging agents, theranostics,
and software for managing inflammation and/or cancer in the periphery or central nervous system (TR&D3); and
a method to use extracellular vesicles as a nanotheranostic platform in neuroinflammation (TR&D4). Together
with the Collaborating and Service Projects (CPs and SPs) we will generate next-generation precision platfor...

## Key facts

- **NIH application ID:** 10848981
- **Project number:** 2P41EB024495-06A1
- **Recipient organization:** UT SOUTHWESTERN MEDICAL CENTER
- **Principal Investigator:** MARTIN G POMPER
- **Activity code:** P41 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,436,774
- **Award type:** 2
- **Project period:** 2017-09-15 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10848981

## Citation

> US National Institutes of Health, RePORTER application 10848981, Resource for Molecular Imaging Agents in Precision Medicine (2P41EB024495-06A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10848981. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*